Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute, Dr. Reddy’s - LARVOL DELTA

Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naïve and convalescent populations. (PubMed, Vaccine) - "mRNA vaccination provides markedly superior and sustained antibody responses compared to adenoviral vector vaccine, which is particularly relevant for long-term protection strategies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Autoimmune manifestations recorded after SARS-CoV-2 vaccination. (PubMed, Clin Exp Vaccine Res) - "Nine patients received specific treatments for diagnosed autoimmune diseases (AID), whereas the others showed non-specific immune stimulation, reactive arthritis, myositis, and cerebral venous thrombosis, which improved with symptomatic treatment. This series suggests a link between severe acute respiratory syndrome coronavirus 2 vaccination and triggered or revealed AID or AIM."

Journal • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Myositis • Novel Coronavirus Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Thrombosis

Neutralization and Anti-S Antibody Titers in SARS-CoV-2 Boosted Adults in Mexico: A Comparison Across Five Vaccine Types. (PubMed, Int J Microbiol) - "We observed that the highest anti-protein S GMTs were in the group that received a heterologous booster with BNT162b2, AZD1222, Ad5-nCoV, or CoronaVac; the group without a booster showed the lowest GMTs...Boosters increased GMTs for all people, independently of their primary vaccine scheme. Yet, our findings suggest that a heterologous booster produced higher titers against SARS-CoV-2 protein S. Efforts should be made to reach people who received AZD1222 and Ad5-nCoV as their primary scheme and did not get boosted, as neutralization in those groups was particularly low."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PROS1

Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial. (PubMed, Vaccine) - P3 | "15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunization route-mediated differences in long-term maturation of humoral immune response induced by adenovirus vector-based COVID-19 vaccine Sputnik V in nonhuman primates. (PubMed, Front Immunol) - "Unlike IN vaccination, IM vaccination also resulted in a continuous long-term increase in serum maturation parameters such as antibody avidity, neutralization potency and breadth. The present study provides valuable information about distinct features of the long-term postvaccination humoral immune response in nonhuman primates induced by adenoviral COVID-19 vaccine administered by the intramuscular and intranasal routes commonly used in clinical practice."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Development and Clinical Validation of a Skin Test for In Vivo Assessment of SARS-CoV-2 Specific T-Cell Immunity. (PubMed, Viruses) - "An integrated clinical analysis included 374 volunteers stratified by vaccination status (EpiVacCorona, Gam-COVID-Vac, CoviVac) prior to COVID-19 infection (Wuhan/Alpha, Delta, Omicron variants), and SARS-CoV-2-naïve controls...047119). Its high safety profile and consistent performance across diverse cohorts support its utility for mass screening and monitoring of cellular immune protection following infection or vaccination."

Journal • Preclinical • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4

Neighborhood enrichment for the identification of antigen-specific T-cell receptors. (PubMed, Brief Bioinform) - "While murine datasets provide valuable insights into algorithm performance, caution is advised when extrapolating these results to other species or different experimental conditions. TCRgrapher is freely available on GitHub (https://github.com/KseniaMIPT/tcrgrapher), offering researchers a robust tool for investigating TCR specificity and advancing immunological studies."

Journal • CNS Disorders • Immunology • Infectious Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Adverse events of special interest after vaccination with COVID-19 vaccines: a cohort event monitoring study in Iran. (PubMed, Eur J Med Res) - "We found around one AESI among every 8,000 vaccinated Iranian people. The incidence of AESIs after COVID-19 vaccines was relatively rare and the studied vaccines can be considered safe. AZD1222 had a higher incidence of AESIs. Coagulation disorders, and generalized seizure were the main and most common AESIs."

Adverse events • Journal • Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Endocrine Disorders • Epilepsy • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease

Evaluation of T cell immune memory response after BBIBP-CorV, gam-COVID-Vac, and heterologous gam-COVID-Vac /mRNA-1273 COVID-19 vaccination schemes against different SARS-CoV-2 variants. (PubMed, Vaccine) - "This study provides new data on effective humoral and cellular immune responses against the ancestral WT virus as well as the Gamma and Omicron variants. Moreover, memory CD4+ and CD8+ T cell responses remain protective, and the heterologous scheme may elicit stronger T cell responses against emerging variants."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Evaluating miscarriage incidence after COVID-19 vaccination. (PubMed, Sci Rep) - "This cohort study included 26,701 women of reproductive age (15-49) who were vaccinated with different vaccines (Sinopharm, Sputnik V, AZD1222 and CoVIran Barekat) between April 2021 and August 2022 in seven cities in Iran...In general, the miscarriage rate in women of reproductive age was 4.8 (95% CI 4.1-5.7) per 1000 women. The estimated incidence rates were not higher than expected; therefore, it can be argued that COVID - 19 vaccination with Sputnik V, Sinopharm, Barekat and AZD1222 does not increase the probability of miscarriage and the vaccines are therefore safe in this respect."

Journal • Infectious Disease • Novel Coronavirus Disease

FH-63: Phase IIB Study of Recombinant Novel Coronavirus Vaccine (clinicaltrials.gov) - P2 | N=88 | Completed | Sponsor: Fundación Huésped | Active, not recruiting ➔ Completed | Phase classification: P2b ➔ P2 | N=450 ➔ 88

Enrollment change • Phase classification • Trial completion • Infectious Disease • Novel Coronavirus Disease

THE AGE AND TYPE OF THERAPY NEGATIVELY INFLUENCE THE FORMATION OF ANTIBODIES TO SARS-COV-2 VIRUS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS (CLPD) (EHA 2025) - "33 patients received therapy using monoclonal antibodies (daratumumab - 18; rituximab - 15), chemotherapy - 21, without treatment - 3 subjects... Our study demonstrates that decreased production of Abs to the SARS-CoV-2 virus in patients with CLPD is associated with age and daratumumab use. Daratumumab therapy can lead to rapid depletion of gamma globulins and NK cells. Some studies have shown that approximately 6 months after discontinuation of daratumumab, gamma globulin and NK cell levels recover."

Clinical • Hematological Malignancies • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

A review of currently licensed mucosal COVID-19 vaccines. (PubMed, Vaccine) - "This highlights the importance of expanded research in this field. In this review, we aim to summarize what is known about these currently licensed vaccines, with an emphasis on the key findings obtained in both preclinical and clinical studies."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The effect of phycocyanins from Arthrospira platensis on the efficacy of immunization with an anti-coronavirus vaccine in vivo (PubMed, Vopr Pitan) - "The manifestation of the Module effects, in contrast to the PC concentrate, is apparently due to its better stability in the gastrointestinal tract environment. Further studies of the secretory activity of immunocompetent cells are needed, which may shed light on the nature of the effect of PC on key parts of the immune system."

Journal • Preclinical • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A comparison of Gam-COVID-Vac vaccination and non-vaccination on neurological symptoms and immune response in post-COVID-19 syndrome. (PubMed, Qatar Med J) - "Although certain neurological symptoms may continue, immunization has a beneficial influence on their progression. The results emphasize the crucial role of an increased humoral immune response in individuals with post-COVID-19 syndrome, but do not show significant changes in T-cell immune parameters."

Journal • CNS Disorders • Infectious Disease • Novel Coronavirus Disease • Pain • Sleep Disorder

Triple Rare Thrombosis Including Portal Vein Thrombosis Associated with Vaccine-Induced Immune Thrombotic Thrombocytopenia after Gam-COVID Vac Vaccination (APASL 2025) - "Introduction: The incidence of vaccine-induced immune thrombotic thrombocytopenia (VITT) ranged from 3.2 to 16.1 cases per million after the viral vector vaccines ChAdOx1-S (AstraZeneca, UK) and was 4 times lower after Ad26.COV2.S (Johnson & Johnson, США)...Case description: A 36-year-old woman developed fever above 39.5°C, severe headache, generalized seizure, shortness of breath and abdominal pain 10 days after her first dose of Gam-COVID-Vac (consisting of two recombinant adenovirus vector components, type 26 (rAD26) and type 5 (rAd5), both encoding the S glycoprotein of the SARS-CoV-2 virus (rAD26-S and rAD5-S)...Anticoagulation therapy with rivaroxaban was continued for 6 months until complete resolution of PVT... VITT is a very rare but life-threatening condition characterized by the development of thrombosis, including rare localizations in the setting of thrombocytopenia. In the present case, early diagnosis and early anticoagulant therapy resulted in..."

Anemia • Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Epilepsy • Gastroenterology • Genetic Disorders • Hematological Disorders • Hepatology • Immune Thrombocytopenic Purpura • Novel Coronavirus Disease • Pain • Paroxysmal Nocturnal Hemoglobinuria • Pneumonia • Portal Hypertension • Rare Diseases • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis • ERCC6

Assessment of the factors affecting the clinical outcomes of infection and safety of vaccines against SARS-CoV-2 among Egyptian patients. (PubMed, BMC Infect Dis) - "Vaccination, particularly with BBIBP-CorV (Sinopharm), significantly reduces COVID-19 severity among Egyptians, despite various clinical presentations and hematological effects."

Clinical data • Journal • Retrospective data • Cardiovascular • Diabetes • Hematological Disorders • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases

Report on adverse events of COVID-19 vaccines in Iran: a comprehensive national prospective longitudinal analysis. (PubMed, Front Immunol) - "Serious AEs were more frequently associated with Sputnik V and Vaxzevria (AstraZeneca), with 0.73 and 0.64 cases per 10,000 injections, respectively. Coagulation and thrombosis disorders were the most common serious AEs (29%), followed by neurological (24.7%) and cardiovascular AEs (15.8%). In conclusion, the AEs of COVID-19 vaccination were primarily mild and transient, while serious AEs remained exceptionally rare."

Adverse events • Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Thrombosis

Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used. (PubMed, Vaccines (Basel)) - "Compared with the Comirnaty, Covilo, and Vaxzevria vaccines, the Spikevax vaccine induced significantly greater headache intensities...This knowledge is clinically relevant in differentiating life-threatening vaccination complications, such as thrombotic syndromes, which are also associated with headaches. Based on these results, new diagnostic criteria for postvaccinal headaches can be developed."

Journal • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases

Safety and Adverse Effects Related to COVID-19 Viral Vector Vaccines: A Systematic Review. (PubMed, Tanaffos) - "There have been safety concerns regarding the COVID-19 vaccines because of their unprecedented speed of development...Erythema, swelling, tenderness, itching, and numbness at the injection site are the most common local reactions. It appeared that the frequency of serious adverse events is negligible, and vaccination to prevent severe COVID-19 and mortality has greater benefits than adverse events in the general population."

Adverse events • Journal • Review • Cardiovascular • Dermatology • Fatigue • Hematological Disorders • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Pain • Respiratory Diseases • Thrombosis

Empowering African Expertise: Enhancing Safety Data Integration and Signal Detection for COVID-19 Vaccines Through the African Union Smart Safety Surveillance Joint Signal Management Group. (PubMed, Drug Saf) - "The JSM group established a scalable and replicable model for future signal management of other priority health products in low- and middle-income countries, fostering ongoing collaboration and capacity building. Knowledge and experience gained from this pilot initiative will guide stakeholders in future safety surveillance initiatives within the African continent."

Journal • Infectious Disease • Novel Coronavirus Disease

Diagnosis of Hypersensitivity to Components of Anti-COVID Vaccines (AAAAI-WAO 2025) - "18 (72%) believing they were allergic to the vaccine tested negative. Conclusions Patients with a history of anaphylaxis following vaccination should undergo allergy testing for vaccine components."

Asthma • Dermatology • Immunology • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • Urticaria

Impact of COVID-19 vaccination on lower urinary tract (LUTS) in benign prostatic hyperplasia (BPH) patients. (PubMed, Clin Exp Vaccine Res) - "This prospective longitudinal study conducted at Sina Hospital in Tehran, Iran, from September 2022 to March 2023 enrolled 106 BPH patients receiving COVID-19 vaccines...Other symptoms showed no statistical differences. Our findings elucidate that urgency, dysuria, frequency, and hematuria may be exacerbated after COVID-19 vaccination in BPH patients."

Journal • Benign Prostatic Hyperplasia • Infectious Disease • Novel Coronavirus Disease • Prostate Cancer • Respiratory Diseases

Globally approved vaccines for COVID-19: a systematic review. (PubMed, Braz J Microbiol) - "The vaccines included in this study were: Cominarty, mRNA-1273 or Spikevax, Vaxzevria or AZD1222 or Covishield, CoronaVac or PicoVacc, and Ad26.COV2.S, SputnikV or Gam-Covid-Vac, Covaxin, NVX-CoV2373 or Covovax or Nuvaxovid, WIV04 and HB02, CoVLP or Covifenz and Convidecia or Ad5-nCoV...All vaccines evaluated have different compositions, dosages, populations, and study designs. All are effective in at least preventing symptomatic COVID-19, causing mild or moderate adverse effects when present."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Vaccine Effectiveness Against Severe Acute Respiratory Infections (SARI) Hospitalizations Associated with Laboratory-Confirmed SARS-CoV-2 in Ghana from June 2022 to March 2024 (ASTMH 2024) - "A total of 118 (7%) patients tested positive for the SARS-CoV-2 of whom 29 (25%), were vaccinated with primary vaccine series (Sputnik V, Vaxzervria, JCovden, Spikevax or Comirnaty) and 60 (51%) were females...For those who had been vaccinated with the primary series, 14-179 days previously, the absolute VE against COVID-19 SARI hospitalization was 25% (95%CI: -60.7 to 79.0%) and the seasonal VE was 22% (95% CI: -60.3% to 78.1%) but waned after 6 months of vaccine uptake. COVID-19 vaccines deployed in Ghana prevented one in four COVID-19 associated SARI hospitalizations in the first 6 months over the study period, but protective effectiveness probably waned with time as reported in other countries, reflecting potential benefit from booster vaccination."

Clinical • Late-breaking abstract • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases